Project Grant R44CA295245
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This $400,000 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel pan-cancer CAR-T product targeting MR1, a non-classical MHC molecule expressed on the surface of a variety of tumor cells. The funding will be used by Kure Ai Inc. to: 1) assess MR1 cell surface expression in primary AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3) evaluate the safety of the MR1 CAR-T...
This $994,859 Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports Cytoagents Inc.'s development of CTO1681, a novel compound intended to prevent and mitigate cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. The funding will enable a Phase 1b clinical trial to evaluate the safety, pharmacokinetics, and potential impact of CTO1681 on CRS and...
The National Cancer Institute awarded a $195,766 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Yale University for the "Synthetic Mechano-Transduction for Improved Cell Therapies in Immuno-Oncology" project. The purpose of this award is to develop an innovative approach that harnesses mechanical forces to enhance the efficacy and safety of Chimeric Antigen Receptor (CAR) T-cell therapies for solid tumors. The project aims to engineer a...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $1,313,806 in funding to develop and translate chimeric antigen receptor (CAR) T-cell therapies targeting mesothelin for solid tumor treatment. The key products and services to be delivered include: Conducting clinical trials to evaluate the safety and efficacy of mesothelin-targeted CAR T-cell therapies, including...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,958 to Mabswitch Inc., a minority-owned small business, to assess the feasibility of regulating the activation, effector functions, and cytokine release of chimeric antigen receptor (CAR) T-cell therapies. The project aims to develop a "switchable affinity CAR" (SAEFCAR) that can be controlled by an exogenously administered ligand, potentially mitigating the toxicity...
This $1,477,396 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope supports the development of a novel approach to improve the efficacy and durability of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with B-cell non-Hodgkin's lymphoma (B-NHL). The key products and services to be delivered under this award include: Conducting two pilot clinical trials to establish the...
This $415,257 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research by the Methodist Hospital Research Institute (HMRI) in Houston, Texas. The project aims to explore the role of stress granules, which are cellular structures that accumulate during chronic T cell activation, in contributing to CAR-T cell exhaustion. Specifically, the research will analyze the dynamics of stress granule assembly and maintenance in...
The National Cancer Institute (NCI) awarded a 5-year, $432,837 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University. The grant will fund research to define optimal CAR T cell subsets for treating large B cell lymphoma (LBCL) and overcome immunosuppressive T regulatory (Treg) cells that limit CAR T cell efficacy. Key objectives include: 1) using single-cell sequencing to identify CAR T cell clones with desired expansion, persistence,...
The National Cancer Institute awarded a $483,041 Project Grant (CFDA 93.396 Cancer Biology Research) to Baylor College of Medicine to conduct research aimed at improving the efficacy of cancer immunotherapy using engineered T cells. The key objectives are to: 1) understand the molecular mechanisms regulating T-cell dysfunction in the tumor microenvironment, 2) enhance T-cell resistance to dysfunction through systematic engineering of transcription factors, and 3) determine the most effective...
This $587,108 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to enhance the efficacy of non-activated chimeric antigen receptor (CAR) T cells for cancer treatment. The research will investigate methods to improve the transduction efficiency and functional properties of non-activated T cells by modulating type I interferon (IFN1) signaling pathways. Key objectives include: Evaluating the impact of IFN1 blockade on CAR lentivirus transduction...